Compare VLN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLN | CGTX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Israel | United States |
| Employees | 233 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.9M | 94.5M |
| IPO Year | N/A | 2021 |
| Metric | VLN | CGTX |
|---|---|---|
| Price | $1.52 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $3.33 |
| AVG Volume (30 Days) | 658.7K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.37 | N/A |
| Revenue Next Year | $16.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.22 |
| 52 Week High | $3.34 | $3.83 |
| Indicator | VLN | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 55.54 |
| Support Level | $1.40 | $1.01 |
| Resistance Level | $1.63 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 41.67 | 64.99 |
Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.